We, Delex Pharma International Inc., have successfully blossomed in twelve years of serving our satisfied market and professionally working with our partners. We may not be one of the longest-standing pharmaceutical companies in the country, but we are proud to be among the most reputable, socially accountable, and fastest-growing Pharma industries nationwide.

It all started over a cup of coffee, when our core leaders, after an intensive brainstorming and discussion, finally came to a brilliant decision to start a new venture. From the time it was planned, it led to the establishment of a premier Filipino-owned pharmaceutical company. But before delving into our business, we were duly registered with the Securities and Exchange Commission (SEC) on July 13, 2009.

While we focus on hospitals as our market in the country, we proudly administer the safe distribution of quality and affordable FDA-approved critical care products. It is mainly for intensive care settings, which include the Intensive Care Units, Emergency Rooms, and Operating Theaters. Moreover, we are also into marketing medical supplies and food supplements nationwide. The trading of our products is on a wholesale and retail basis.

Digging in through our business line, we identified a “gap” in the administration of critical care products of companies in the Philippines. Some of these institutions market their products at premium prices. To at least cater to this “gap,” we helped in the distribution of affordable and premier critical care products in the country. Through this action of Delex Pharma, critically ill poor patients can have the quality treatment they deserve. Hence, supporting our tagline “Meeting the Gaps in Critical Care.”

As we carefully decide on every planned move that is worth our investment, we partnered with the leading international pharmaceutical companies that carry the cGMP certification stamp. We opened our doors to stakeholders from Indian, Japanese, and European companies, such as Baxter Philippines (Commercial), Johnson & Johnson Philippines, Inc., United Biotech Pvt. Ltd. (UBPL), Kalbe International, Astellas Pharma Philippines, Inc., and Sandoz Philippines to name a few. Delivering beyond expectations, we gained the trust of our valued partners. At DPI, we walk the talk while embodying excellence and professionalism.

Climbing our way to the top, we ranked third (3rd) in the hospital channel based on the IQVIA report released in 2020.

Furthermore, we provide a variety of services to our clients with our market solutions ranging from sales & marketing, support for product registration & compliance, sales order processing, warehousing, invoicing, delivery & transportation, collections, and distribution of hospital products.

In 2022, DPI acquired MD Pharma and JMN Brothers Pharma Limited, Inc. as its subsidiaries. Both companies cater to the health consumer and hospital businesses.

Delex Pharma has always been and will always be in service of the critical care needs of the hospitals in the country.